Showing results (181-190 of 531) with videos related to
Sort By:
Pageof 54
Journal of Neurology|February 24, 2001
Workshop I: Parkinson's disease and sleep--results of the group discussionP Clarenbach, W Greulich, H M Meinck, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|May 28, 2003
Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorderS Yamada, M Yamamoto, H Ozawa, et al.Journal of Neural Transmission. Parkinson'S Disease and Dementia Section|January 1, 1995
Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's diseaseM Mogi, M Harada, T Kondo, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 1, 1990
Adrenergic-cholinergic imbalances: the physostigmine-syndrome is not antagonized by the MAO-A inhibitor brofaromineJ Fritze, E Sofic, H Pfüller, et al.Mechanisms of Ageing and Development|September 1, 1980
Levodopa in the treatment of (pre) senile dementiaK Jellinger, H Flament, P Riederer, et al.FEBS Letters|July 15, 1999
High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expressionA Neumann, R Schinzel, D Palm, et al.Journal of Neurochemistry|September 1, 1994
Altered brain metabolism of iron as a cause of neurodegenerative diseases?M Gerlach, D Ben-Shachar, P Riederer, et al.Brain Research. Brain Research Reviews|February 1, 1997
Advanced glycation endproducts in ageing and Alzheimer's diseaseG Münch, J Thome, P Foley, et al.Annals of Neurology|January 1, 1992
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's diseaseD Ben-Shachar, G Eshel, P Riederer, et al.Neurotoxicity Research|June 22, 2006
Strategies for the protection of dopaminergic neurons against neurotoxicityM Gerlach, K L Double, M B Youdim, et al.Pageof 54